Why the study?
Does low-dose oral dantrolene improve chronic muscle pain in individuals with malignant hyperthermia susceptibility?
Does low-dose oral dantrolene improve chronic muscle pain in individuals with malignant hyperthermia susceptibility?
Low-dose oral dantrolene may be an effective and safe long-term treatment for chronic muscle pain in individuals with malignant hyperthermia susceptibility.
May support low-dose dantrolene for cramps in MH-susceptible patients; leaves open efficacy and safety in controlled trials.
This case report describes a female with p.Lys4876Arg amino acid change in the ryanodine receptor type 1 (RYR1) and a sibling who died of malignant hyperthermia (MH) during anesthesia. After her diagnosis as MH susceptible, this patient was administered low-dose dantrolene daily for greater than 25 years for treatment of chronic muscle spasm and pain in her lower extremities and back limiting sleep. Her creatine phosphokinase (CPK) was as high as 2390 IU/L during labor and 900 IU at rest. With 25 mg dantrolene daily, muscle cramps were eliminated, and sleep was improved. Gait instability was noted with dantrolene in the morning, but not when taken at bedtime. There was no evidence of liver injury. This case suggests that low dose dantrolene by mouth could be considered for the treatment of chronic muscle pain in individuals with MH susceptibility.
No takes yet. Share an insight, caveat, or question.
Butala et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: